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Background and purpose: Avascular necrosis (AVN) is one of the common complications 
after closed reduction and hip spica cast for developmental dysplasia of the hip (DDH). Prereduc-
tion traction has been used to reduce a dislocated hip or decrease the risk of AVN, but there are 
conflicting results in prevention effects on AVN. The purpose of this study was to systematically 
review the current literature and evaluate the effect of prereduction traction in preventing AVN 
in children with DDH treated by closed reduction through a meta-analysis.
Materials and methods: A systematic review of the literature was performed using PubMed 
and EMBASE with variations of three major terms: 1) hip dislocation; 2) closed reduction; and 
3) avascular necrosis. Seven studies that could compare the incidence of AVN between the trac-
tion and no-traction group were included. Methodological quality was assessed, a heterogeneity 
test was done (p=0.008), and the pooled risk ratios were estimated.
Results: The association between traction and AVN was assessed, using data on 683 hips treated 
by closed reduction. The incidence of AVN in the traction and no-traction groups ranged from 
5% to 47.7% and from 0% to 72.7%, respectively. A meta-analysis with a random effects model 
indicated no significant difference in the incidence of AVN between traction and no-traction 
groups (p=0.536).
Conclusion: There was insufficient evidence to decide the efficacy of prereduction traction 
before closed reduction in reducing the risk of AVN in patients with DDH in this meta-analysis. 
To recommend prereduction traction for the prevention of AVN, long-term follow-up studies 
considering age, severity of dislocation, and appropriate traction method are needed.
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Introduction
The treatment for developmental dysplasia of the hip (DDH) is mainly based on age.1–3 
Patients older than 6 months are treated with closed reduction and hip spica cast because 
the success rate of Pavlik harness is decreased due to the larger and increasingly active 
child. The success rate after closed reduction and hip spica cast has been reported to 
be up to 95%; however, the incidence of avascular necrosis (AVN) has been reported 
to be from 0% to 73%.3,4 AVN has been reported to compromise acetabular develop-
ment and may result in complications such as abnormal gait, leg length discrepancy, 
pain, and degenerative joint disease.5–8
The exact etiology of AVN is still unknown and seems to be related to various 
mechanical and biological factors.9–14 Commonly proposed mechanisms are direct vascu-
lar compression and excessive pressure on the femoral head.10 For the prevention of AVN, 
the presence of the ossific nucleus at the time of reduction, positioning in immobilization, 
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and prereduction traction have been discussed.13,15 Prereduction 
traction had been recommended with the belief that the traction 
would stretch the soft tissues that create excessive pressure 
on the femoral head after reduction, resulting in AVN.2,6
However, there are conflicting results in the literature 
about the prevention effect of prereduction traction on 
AVN. Other studies found that traction did not influence the 
incidence of AVN and requires many accretional resources, 
such as a longer hospital stay.16 Moreover, Weinstein pointed 
out that the intraarticular obstacles would not be affected by 
traction.17 Although there is a trend toward a decreasing use of 
traction, prereduction traction remains as a treatment tradition 
or a gesture toward a medico-legal environment.18
Previous studies evaluated AVN with a diverse clas-
sification, and the traction method was also variable, so it 
is difficult to estimate the severity of AVN or compare the 
effect of variable traction methods. This study focused on 
the presence of AVN after closed reduction and hip spica 
cast. The purpose of the study is to determine the efficacy of 
prereduction traction in reducing the incidence of AVN after 
closed reduction in DDH through a meta-analysis.
Materials and methods
search strategy and criteria
We searched PubMed and EMBASE using variations of 
three key terms: 1) hip dislocation; 2) closed reduction; and 
3) avascular necrosis. Search parameters were restricted 
to English language studies of pediatric populations. Data 
were extracted from PubMed and EMBASE according to 
Figure 1. Two authors independently reviewed the title and 
abstract of each article identified in the literature search. 
When eligibility was unclear from the title and abstract, 
the full text of the article was obtained and evaluated for 
eligibility. At each stage, disagreements were discussed 
and resolved in a consensus meeting along with the 
senior reviewers before the next step was carried out.
inclusion and exclusion criteria
All retrospective and prospective studies of DDH where trac-
tion was used as a treatment modality and AVN was evalu-
ated as a result or complication of treatment of DDH were 
included. Articles were excluded based on the following exclu-
sion criteria: 1) studies where neuromuscular or teratologic hip 
dislocations were present; 2) studies where subluxations had 
been included in the population and not analyzed separately; 
3) studies conducted before 1969, when Salter suggested the 
criteria for AVN;5 4) studies where AVN had not been evalu-
ated as an independent result; and 5) studies where traction had 
not been evaluated as an independent effect modifier.
assessment of study type and quality
The Oxford Centre for Evidence-Based Medicine Levels 
of Evidence table for the orthopedic literature was used by 
two authors to independently assess the included studies and 
assign a level of evidence (I–V).19 The methodological quality 
of the included studies was assessed using Methodological 
Index for Nonrandomized Studies (MINORS) checklists.20 
According to the MINORS checklist, noncomparative stud-
ies were evaluated with eight items, with each rated from 
0 to 2 points. The items were study aim, consecutive patients, 
prospective design, appropriate end points, unbiased assess-
ment, follow-up, dropout rate, and sample size calculation. 
Additional items, including adequate control group, con-
temporary groups, baseline group equivalence, and adequate 
statistical analysis, were used for comparative studies. The 
maximum possible scores were 16 and 24 for noncomparative 
and comparative studies, respectively. The quality scoring 
of studies was directly proportional to their methodological 
strength with a maximum possible score. No randomized 
controlled trials were included. All the studies were retro-
spective and Level III. The median MINORS score for the 
noncomparative studies was 8 (range 7–8), and the median 
score for comparative studies was 13 (range 12–16).
Meta-analysis methodology
Treatment effects were reported as the relative risk. The 
meta-analysis was weighted by the sample size of each 
study. The hypothesis of statistical heterogeneity was tested 
using the Cochran’s Q-test, with statistical significance set 
at the two-tailed 0.10 level, whereas the extent of statistical 
consistency was measured with I2, defined as 100% × (Q - 
df)/Q, where Q is Cochran’s heterogeneity statistic and df 
is the degrees of freedom. Binary outcomes from individual 
studies were analyzed to compute individual and polled 
risk ratios, with a pertinent 95% CI, by means of an inverse 
variance method. A fixed effects model was used in case of 
low statistical inconsistency (I2,25%) or a random effects 
model (which better accommodates clinical and statistical 
variations) was used in case of moderate or high statistical 
inconsistency (I2.25%). We completed all analyses using 
Comprehensive Meta-Analysis version 2.0 (Biostat Inc., 
Englewood, NJ, USA).
Results
study selection
A total of 785 records were identified. After removal of 
duplicate citations, 391 and 394 reports were obtained, 
respectively (Figure 1). A total of 554 articles were obtained 
after exclusion of 240 overlapping articles, and 487 studies 
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were excluded based on the title and abstract; 67 articles 
were found to be eligible for initial screening according to 
the inclusion and exclusion criteria. Of the 60 full texts that 
were excluded, 21 were nonprimary, 11 had insufficient 
follow-up data, 22 also included an open reduction procedure, 
and 6 did not report on osteonecrosis data. This resulted in 
seven studies3,8,16,21–24 to be included in the present systematic 
review. Six studies were unanimous selections, and one was 
selected after a consensus meeting;24 it reported the effect of 
traction, including both closed reduction and open reduction, 
but the relevant data were extracted, and hence the paper 
was included.
study characteristics and data collection
All seven studies were observational studies in design. They 
had a no-traction group and traction group; however, there 
was no random allocation to the groups in any of the studies. 
The total number of hips included in a study ranged from 36 
to 342. The age at the time of surgical reduction ranged from 
1 to 55 months. The follow-up duration ranged from 0.5 to 
40 years. Although all studies involved traction, the purpose 
of each study was slightly different. Three studies described 
the association of traction with AVN.3,16,21 Sibinski et al23 
dealt with the clinical course of traction, Brougham et al8 dis-
cussed the clinical outcome of closed reduction and focused 
on AVN of the femoral head, Kutlu et al21 discussed the 
clinical outcome of closed reduction, and Ishii and Ponseti22 
examined the effect of the femoral head ossific nucleus on 
the incidence of AVN after DDH treatment. The outcome and 
design of each study are summarized in Table 1. Although the 
purpose and methods were slightly different, data extraction 
for analysis was possible, to compare the incidence of AVN 
between the traction and no-traction groups (Table 2).
Closed reduction was done in 966 hips, of which traction 
was performed in 683 hips but not in 283 hips. The incidence 
of AVN in the traction and no-traction groups ranged from 
5% to 47.7% and from 0% to 72.7%, respectively. In the 
diagnosis and classification of AVN, the most commonly 
used Salter criteria5 for total AVN (Figure S1) was used in 
four studies. The Gage and Winter classification6 (Figure S2) 
that provided a definition of partial AVN was used in three 
studies. The Bucholz and Ogden classification25 (Figure S3) 
that noted delayed presentation of lateral physeal arrest 
was used in two studies. However, there was only a short 
description on the involvement of the epiphysis or metaphy-
sis in the included studies. Radiological criteria were used 
to assess the adequacy of reduction in two studies and were 
not clarified in the remaining five. Besides the prereduction 
traction, we could identify other variables related to AVN; 
adductor tenotomy was performed in four studies and abduc-
tion brace in two.
Meta-analysis
Statistical analysis with the random effects model did not 
demonstrate a significant difference in the incidence of AVN 
between the traction and no-traction groups (risk ratio 0.86; 
Number of records identified through
database searching (total N=785)
PubMed
n=391
554 studies screened
67 full-text articles
assessed for eligibility
7 studies included in
quantitative synthesis
487 studies excluded based on title
and abstract
240 studies excluded by duplicates
EMBASE
n=394
•  Nonprimary (n=21)
•  Minimum follow-up <2 years (n=11)
•  Including open reduction (n=22)
•  Unable to extract osteonecrosis data (n=6)
60 studies excluded:
Figure 1 systematic search strategy results.
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95% CI=0.52–1.40; p=0.536) (Figure 2). The outcomes of the 
studies included in the meta-analysis demonstrated statistical 
heterogeneity (Q=17.50, I 2=65.72, p=0.008), and the random 
effects model was used. No publication bias was detected by 
the funnel plot analysis and Egger’s test (p=0.408).
The factors related to traction are summarized in Table 3. 
The position of the hip and knee during traction varied, and 
the duration ranged from 1 to 56 days. The position and 
duration of the cast after traction also varied. In all studies, 
there was no indication for termination of traction. Various 
factors other than preliminary traction were observed, but 
subgroup analysis could not be performed because common 
parts were not found. No study utilized statistical adjustments 
to control for the potential confounders.
Discussion
The treatment of choice of DDH has been established and 
standardized based on long-term follow-up and a large 
database.26–29 The timing of diagnosis is important, because 
the treatment of DDH diagnosed in patients over 6 months 
old is usually done under anesthesia compared to the Pavlik 
harness in patients under 6 months old.30 Without underlying 
disease, the most common treatment in children aged 
6–24 months with DDH is closed reduction and hip spica 
cast under general anesthesia.31,32 Despite the standardized 
method following age groups, the use of prereduction trac-
tion for proper reduction and preventing AVN before closed 
reduction is still controversial.1,33,34 The risk of AVN was 
reported to be as high as 73% after closed reduction.3 The 
exact etiology of the high AVN rate after treatment is still 
unknown but is likely multifactorial.35 Previous studies had 
focused on various factors related to AVN, including age, 
sex, hip abduction angle in cast, and prereduction traction. 
In this meta-analysis, we evaluated whether the prereduction 
traction can decrease the risk of AVN.
Prereduction traction had been described as a method 
that might decrease the risk of AVN.3,12,31,36,37 AVN is a 
multifactorial problem, and prereduction traction is one of 
the variables associated with AVN. In the previous studies, 
there were discrepancies in age,12,27 position of traction,7,31 
duration of traction,12,24,28 traction weight,25,31 and severity of 
dislocation.22,26 Besides, although application of traction is 
Table 1 Population characteristics
Author Year Outcome of the 
study
Clinical 
setting
Age at reduction 
(months)
Follow-up 
(years)
Classification of 
AVN
Other variables
Kutlu et al21 2000 The effect of traction Traction 8.1 (1.5–20) 5 (1–12.3) salter5 adductor tenotomy
no-traction 7.2 (1.5–12) 2.5 (1–3)
langenskiold 
and Paavilainen3
2000 The effect of traction Traction 6–36 14 Their own no other factors
no-traction 11
Brougham 
et al8
1990 The extent of avascular 
necrosis
Traction 14 (1–55) 12 (6–17) salter5 adductor tenotomy
no-traction gage and Winter6 abduction device
ishii and 
Ponseti22
1978 The displacement of the 
femoral head
CR under
1 year
7 (2–12) 15.1 (8–29) salter5 adductor tenotomy
gage and Winter6
sibinski et al23 2006 The effect of traction Traction 14.2 (6–32) 20.7 (14–40) Bucholz and Ogden25 abduction brace
no-traction 16.2 (6–32)
segal et al24 1999 The protective influence 
of the ossific nucleus
aVn 6 (3–9) 4.4 (0.7–15.2) salter5 adductor tenotomy
absence of aVn 6 (2–11) 3.0 (0.5–10.2) gage and Winter6 Pavlik harness
sucato et al16 2017 The effect of traction Traction 10.8 (2.4–33.6) 10.4 (2.0–27.7) Bucholz and Ogden25 no other factors
Note: Values in parentheses are minimum and maximum.
Abbreviations: aVn, avascular necrosis; CR, closed reduction.
Table 2 Onset and risk ratio of aVn at the time of follow-up
Author Number of hips Number of AVN Risk 
ratioTraction No-traction Traction No-traction
Kutlu et al21 89 65 4 0 6.6
langenskiold and Paavilainen3 65 33 20 24 0.423
Brougham et al8 168 42 80 19 1.053
ishii and Ponseti22 7 33 1 11 0.429
sibinski et al23 107 48 31 20 0.695
segal et al24 33 4 12 1 1.455
sucato et al16 168 40 30 3 2.381
Abbreviation: aVn, avascular necrosis.
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relatively simple and performed without anesthesia, there are 
problems caused by the expense of additional hospitaliza-
tion or the discomfort of patients. In contrast, there are also 
many studies that have not found any relationship between 
prereduction traction and the incidence of AVN.8,16,34,36 
Furthermore, a recent study found that the use of prereduction 
traction was even significantly associated with both the 
development of AVN and an increased rate of AVN.38 In 
this meta-analysis, there was no significant difference in 
the presence of AVN between the prereduction traction and 
no-traction groups.
Two studies in this meta-analysis showed a significantly 
lower incidence of AVN in the prereduction traction group. 
Sibinski et al23 analyzed two groups: in children older than 
1 year, the risk of growth disturbances of the proximal femoral 
epiphysis was significantly reduced in the traction group; 
however, in children younger than 1 year, physeal arrest 
occurred in 13/41 patients treated with traction and 4/17 
patients treated without traction, which was not statistically 
significant. Langenskiold and Paavilainen3 described that 
prereduction traction decreases the incidence of AVN of the 
femoral head in children aged 6–36 months. However, 86 hips 
without traction were treated before 1957, and 176 hips with 
traction were treated after 1957. There may be an improve-
ment in the reduction position or cast technique and quality 
of radiography. The incidence of AVN was 14.3% in traction 
group and 33.3% in no-traction group in the study by IIshii and 
Ponseti.22 However, traction was applied in only seven hips, 
and we could not confirm whether 15 patients who underwent 
adductor tenotomy were in the traction or no-traction group.
Meanwhile, three studies of our series confirmed that the 
relationship between preliminary traction and the occurrence 
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Figure 2 Meta-analysis of the effect of prereduction traction on the prevention of aVn.
Abbreviation: aVn, avascular necrosis.
Table 3 Variables associated with the use of traction
Author Direction Weight Position in traction Duration (days) Cast position Cast duration
Kutlu et al21 longitudinal 
bilateral
0.5–1.5 kg for 
each leg
Hip flexion 45° 9 (7–21) human position 3 months
hip abduction neutral
Knee mild flexion
langenskiold 
and Paavilainen3
Trunk 
direction
2–4 kg hip and knee 
extension
14–28 lorenz frog position 4–6 months
Brougham 
et al8
n/a n/a hip abduction
60° or 90°
12 (1–28) n/a n/a
ishii and 
Ponseti22
Overhead n/a Bryant’s traction 8 Hip flexion 100°
hip abduction 60°–70°
3 months
(6 weeks–6 months)
sibinski et al23 longitudinal 
bilateral
Until both 
buttocks were 
off the bed
Hip flexion 90°–100°
hip abduction 20°
Knee extension
17 (10–40) Modified Lorenz position 
Hip flexion more than 100° 
hip abduction less than 70°
3 months and
lange cast for next 
2 months
segal et al24 n/a n/a n/a 14–56 human position: 32 children n/a
Frog-leg: 1 child
n/a: 24 children
sucato et al16 Overhead Until flat hand 
under buttock
Bryant’s traction 20.3
(6.3–51.8)
n/a n/a
Abbreviation: n/a, not applicable.
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of AVN was not statistically significant. Kutlu et al21 
compared two groups similar in age, sex, side, and level of 
dislocation with consistent method and duration of immobili-
zation and found no significant differences. Brougham et al8 
demonstrated that the incidence of AVN was not influenced 
by traction in average 14 months (1–55 months) of age at 
reduction and average 12 days (1–28 days) of prereduction 
traction. Sucato et al16 analyzed a total of 208 hips with 
DDH and successful closed reduction, which were treated 
with prereduction Bryant’s traction before closed reduction. 
They included only patients under 3 years of age at the time 
of reduction and found that preoperative Bryant’s traction 
has no protective effect on the development of AVN. In the 
study of Segal et al24 that evaluated the protective influence 
of the ossific nucleus in AVN, the incidence of AVN was 
higher in the traction group (36.4%) than in the no-traction 
group (25%).
The efficacy of prereduction traction was questioned with 
strong arguments by Weinstein in 1997.34 He indicated that 
the incidence of proximal femoral growth disturbance varies 
widely because of the variety of classification systems (Salter 
et al,5 Tönnis,39 Bucholz and Ogden,25 and Kalamchi and 
MacEwen40) and the lack of research about the interobserver 
and intraobserver reliability. The direction and location of the 
traction can affect the outcome. There are three main ways to 
operate the traction: horizontal, vertical overhead (Bryant’s 
traction), and transitional horizontal-to-vertical with gradual 
abduction. To stretch the psoas muscle, the major obstacle 
in closed reduction, the direction of traction is important, 
and the efficacy may be different between horizontal trac-
tion and Bryant’s traction. In addition, because the weight 
and direction of traction change with time, it is not easy to 
find the effect of traction on proximal growth disturbance.35 
Furthermore, forced abduction or forced abduction with 
internal rotation is one of the important risk factors for the 
increased incidence of proximal femoral growth disturbance, 
but this variable was not considered in many previous studies 
regarding traction.29
This meta-analysis has several limitations. We included 
studies conducted after 1969, but traction has been used previ-
ously and larger data may be available if we included studies 
conducted before 1969. However, the most commonly used 
diagnostic criteria for AVN were established by Salter et 
al5 in 1969, so we included studies conducted after 1969 
for the reliability of meta-analysis. The incidence of AVN 
depends on the rigor with which the diagnosis is sought and 
the strictness of adherence to the criteria.27 The Salter criteria5 
is used for AVN within 1 year after treatment but is less 
useful for longer follow-up period. However, type II pattern 
in Bucholz–Ogden25 is not visible till after 5 years of age. The 
inconsistency in classification is the limitation of this study; 
in addition, there is insufficient evidence on the efficacy 
of prereduction traction for AVN because of this problem. 
Age at reduction was not uniform across the studies. Three 
studies8,19,20 did not place age limits on the design itself, and 
other three3,16,24 were age-restricted to 6–48 months, younger 
than 12 months, and below 3 years of age. Studies considering 
age, traction method, severity of dislocation, and secondary 
procedure are needed to support the efficacy of pre-reduction 
traction for the prevention of AVN.
Conclusion
This meta-analysis demonstrated that there is insufficient 
evidence with regard to the efficacy of prereduction trac-
tion before closed reduction in reducing the risk of AVN in 
patients with DDH. Before closed reduction in patients with 
DDH, pediatric orthopedic surgeons should consider variable 
factors related to AVN and additional hospital resources or 
parents’ effort in using the traction. To recommend prereduc-
tion traction for the prevention of AVN, long-term follow-up 
studies considering age, severity of dislocation, and appropri-
ate traction method are needed.
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Figure S1 Criteria for total aVn.
Abbreviation: aVn, avascular necrosis.
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Figure S2 Criteria for partial aVn.
Abbreviation: aVn, avascular necrosis.
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Figure S3 Bucholz and Ogden1 classification.
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